For Immediate Release
September 08, 2004
Contact:
Carolyn Hawley
Canale Communications for Orion Genomics
619-849-5375
carolyn@canalecomm.com
ST. LOUIS, MO September 8, 2004 - Orion Genomics, a "second code" biotechnology company, announced today that the first stage of its agreement with North Carolina State University (NCSU) to sequence large parts of the tobacco genome has been completed, and that the agreement has been extended. The extension more than doubles payments to Orion under the company's subcontract for a portion of the $17.6 million provided to NCSU by Philip Morris USA as part of the 4 ½-year Tobacco Genome Initiative. Led by NCSU investigators, the Initiative aims to provide public and private plant researchers with tobacco genetic information.
"In the initial phase of the tobacco sequencing project, we compared several different methodologies for the discovery of most of tobacco's genes," said Dr. Charles Opperman, professor of plant pathology and genetics at NCSU and leader of the Initiative. "We've determined that Orion's GeneThresher technology rapidly and accurately separates coding from the so-called 'junk DNA' that makes up most of the tobacco genome."
Under the extended agreement, the Initiative will now apply Orion's GeneThresher™ technology to the development of an overall map of the tobacco genome that will identify up to 90 percent of tobacco's genes.
"The successful completion of the first discovery phase of the tobacco genome sequencing project validates Orion's GeneThresher technology in another important plant species," said Nathan Lakey, CEO of Orion Genomics. "The commercialization of GeneThresher is an integral part of our business strategy, and we are pleased at GeneThresher's continuing success as the most rapid and cost-effective plant genome sequencing technology available."
About the Tobacco Genome Initiative
The Tobacco Genome Initiative is funded by Philip Morris USA and centered
in the College of Agriculture and Life Sciences at North Carolina State
University to leverage the college's leadership position in genomic sciences.
Begun in December 2002, the goal of the Initiative is to make a physical
map of the tobacco genome and to sequence as many genes as possible by 2007.
Biotechnology at NC State
North Carolina State University, located in Raleigh, has emerged as a national
leader in biotechnology research. Currently there are more than 170 faculty
whose research interests lie within the broad scope of biotechnology. These
faculty are from 24 departments in the five colleges of Agriculture and
Life Sciences, Engineering, Natural
Resources, Physical and Mathematical Sciences, and Veterinary Medicine.
Orion Genomics, the Second Code Company, develops epigenetic research tools and molecular diagnostic products to fulfill the promise of personalized medicine. Orion's lead product is a simple blood-based test that is being developed to identify people at elevated risk for colorectal cancer. The company has active biomarker discovery programs in cancers of the bladder, breast, lung, ovaries and colon, and the company offers genomics services to the medical, agricultural and bio-fuels research communities. Orion Genomics is located in the Center for Emerging Technologies in St. Louis. For more information, visit the Orion Genomics website at http://www.oriongenomics.com.